AU2020248103A1 - Combinations useful in a method for treating sarcoma - Google Patents

Combinations useful in a method for treating sarcoma Download PDF

Info

Publication number
AU2020248103A1
AU2020248103A1 AU2020248103A AU2020248103A AU2020248103A1 AU 2020248103 A1 AU2020248103 A1 AU 2020248103A1 AU 2020248103 A AU2020248103 A AU 2020248103A AU 2020248103 A AU2020248103 A AU 2020248103A AU 2020248103 A1 AU2020248103 A1 AU 2020248103A1
Authority
AU
Australia
Prior art keywords
compound
subject
sarcoma
pharmaceutical composition
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020248103A
Other languages
English (en)
Inventor
Liangxian Cao
Josephine SHEEDY
Robert SPIEGEL
Marla L. Weetall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PTC Therapeutics Inc
Original Assignee
PTC Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PTC Therapeutics Inc filed Critical PTC Therapeutics Inc
Publication of AU2020248103A1 publication Critical patent/AU2020248103A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/475Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/655Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2020248103A 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma Abandoned AU2020248103A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962825017P 2019-03-27 2019-03-27
US62/825,017 2019-03-27
PCT/US2020/025532 WO2020198705A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Publications (1)

Publication Number Publication Date
AU2020248103A1 true AU2020248103A1 (en) 2021-10-21

Family

ID=72609016

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020248103A Abandoned AU2020248103A1 (en) 2019-03-27 2020-03-27 Combinations useful in a method for treating sarcoma

Country Status (11)

Country Link
US (1) US20220152024A1 (enExample)
EP (1) EP3947379A4 (enExample)
JP (1) JP7602481B2 (enExample)
CN (1) CN114096537B (enExample)
AU (1) AU2020248103A1 (enExample)
BR (1) BR112021019170A2 (enExample)
CA (1) CA3134648A1 (enExample)
EA (1) EA202192349A1 (enExample)
IL (1) IL286647A (enExample)
MX (1) MX2021011688A (enExample)
WO (1) WO2020198705A1 (enExample)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (enExample) * 1973-09-20 1977-11-30 Delalande Sa
EP1351691A4 (en) * 2000-12-12 2005-06-22 Cytovia Inc SUBSTITUTED 2-ARYL-4-ARYLAMINOPYRIMIDINES AND ANALOGUES AS ACTIVATORS OF CASPASES AND APOPTOSIS INDUCERS, AND USE THEREOF
US20100297216A1 (en) * 2006-12-20 2010-11-25 Gabizon Alberto A Method for administration of pegylated liposomal doxorubicin
KR20220143164A (ko) * 2012-11-21 2022-10-24 피티씨 테라퓨틱스, 인크. 치환된 리버스 피리미딘 bmi-1 저해제
BR112021002630A2 (pt) * 2018-08-17 2021-05-11 Ptc Therapeutics, Inc. método para tratar câncer pancreático
EA202192167A1 (ru) * 2019-03-11 2022-01-12 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Форма соединения, обладающая повышенной биодоступностью, и ее составы

Also Published As

Publication number Publication date
BR112021019170A2 (pt) 2022-03-03
US20220152024A1 (en) 2022-05-19
JP2022519930A (ja) 2022-03-25
MX2021011688A (es) 2022-01-24
EA202192349A1 (ru) 2022-02-01
CN114096537A (zh) 2022-02-25
EP3947379A1 (en) 2022-02-09
EP3947379A4 (en) 2022-12-21
JP7602481B2 (ja) 2024-12-18
CA3134648A1 (en) 2020-10-01
WO2020198705A1 (en) 2020-10-01
IL286647A (en) 2021-10-31
CN114096537B (zh) 2025-01-10

Similar Documents

Publication Publication Date Title
US11458126B2 (en) DHODH inhibitor for use in treating hematologic cancers
TW202220654A (zh) 用於治療癌症之組合
JP2025032069A (ja) 膵臓癌を治療する方法
US20220152024A1 (en) Combinations useful in a method for treating sarcoma
RU2812782C2 (ru) Способ лечения острого миелоидного лейкоза
AU2020209767B2 (en) Method for treating an acute myeloid leukemia
US20220143016A1 (en) Method for treating a multiple myeloma
EA046841B1 (ru) Комбинации, пригодные в способе лечения саркомы
EA047152B1 (ru) Способ лечения множественной миеломы
RU2830814C2 (ru) Способ лечения рака поджелудочной железы
CN119818513A (zh) 治疗儿科患者的癌症的方法